Latest CytoSeek News
Mar 25, 2021
Osborne Clarke advised Science Creates Ventures on the deal. SCV invested into University of Bristol spin-out CytoSeek, SCV’s first investment since announcing the launch of the fund. CytoSeek is a discovery stage biotech company established to develop next generation cell therapies using artificial membrane-binding protein technology. The start-up has raised £3.5m (led by SCV) and is seeking to get its technology to cancer patients who are currently underserved by existing treatments. SCV has been working closely with CytoSeek since its inception and led a syndicate of new investors that included Parkwalk Advisors, Meltwind, Luminous Ventures and several angel investors in this funding round. The Osborne Clarke team on the CytoSeek investment was led by Partner Matthew Edwards (Picture). Partner Helen Parsonage led on the fund formation, assisted by Partner Erika Jupe on tax.